AAN Presentation
2025 AAN Presentation:
ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease
ADPD 2025 Presentation
2025 ADPD:
Sabirnetug overview and use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study, ALTITUDE-AD.
2025 APDD Summit
2025 APDD Summit:
Sabirnetug overview and use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study, ALTITUDE-AD
2024 CTAD Presentation
2024 CTAD Presentation:
ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer’s Disease
